Completed PHASE2 INTERVENTIONAL 2-arm NCT02292758

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

Sponsor: Academic and Community Cancer Research United

Conditions Colorectal Adenocarcinoma RAS Wild Type Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7

Interventions Bevacizumab Cetuximab Irinotecan Laboratory Biomarker Analysis Placebo

Updated 18 times since 2017 Last updated: Jan 27, 2022 Started: Dec 12, 2014 Primary completion: Mar 20, 2019 Completion: Sep 27, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02292758, this PHASE2 trial focuses on Colorectal Adenocarcinoma and RAS Wild Type and remains completed. Sponsored by Academic and Community Cancer Research United, it has been updated 18 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

18 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2022 [monthly]

Completed PHASE2

▶ Show 13 earlier versions

Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Dec 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE2
Sep 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE2
Aug 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE2
Apr 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE2
Mar 2019 — Apr 2019 [monthly]

Active Not Recruiting PHASE2
Sep 2018 — Mar 2019 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2017 — Mar 2018 [monthly]

Recruiting PHASE2
Feb 2017 — Oct 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Academic and Community Cancer Research United
National Cancer Institute (NCI)

Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Boise, United States , Boston, United States , Green Bay, United States , Hooksett, United States , New Orleans, United States , Rochester, United States , Saint Joseph, United States , Scottsdale, United States , Sioux City, United States and 3 more locations